Teva receives FDA approval for generic ADHD drug

Brand Adderall, made by Britain's Shire plc, had $2 billion in US sales in 2012.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has obtained US Food and Drug Administration (FDA) approval for its generic version of six dosages of Adderall XR capsules for the treatment of attention deficit hyperactivity disorder (ADHD). Brand Adderall, made by Britain's Shire plc (LSE: SHP; Nasdaq: SHPG) had $2 billion in US sales in 2012, according to IMS.

Teva currently sells a generic version of Adderall XR capsules under a 2006 license and distribution agreement with Shire, as part of a settlement of patent litigation between Shire and Teva subsidiary Barr Pharmaceuticals. Under the terms of the agreement, Teva has the right to be supplied product by Shire through April 1, 2014.

Published by Globes [online], Israel business news - www.globes-online.com - on February 14, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Twitter Facebook Linkedin RSS Newsletters גלובס MAD Conference 2017